Electronic Supporting Information (ESI)

Bimetallic Cu-Mn B spinel oxide catalyzed oxidative synthesis of 1,2-disubstituted benzimidazoles from benzyl bromides

Rohit Sharma,^{a#} Firdoos Ahmad Sofi,^{a#} Preeti Rana,^a Prasad V. Bharatam,^{a*}

^a Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, Punjab-160062.

*E-mail: pvbharatam@niper.ac.in

Sr No	Contents
S1	Experimental procedures
S2	Scanned copies of ¹ H, ¹³ C and HRMS spectra of compounds
S3.	References associated with ESI

TABLE OF CONTENTS

S1. EXPERIMENTAL PROCEDURES

S1.1. Chemistry protocols

General. All chemicals were obtained from Sigma-Aldrich Company and used as received. ¹H, ¹³C and DEPT NMR spectra were recorded on Brucker-Avance DPX FT-NMR 500 and 400 MHz instruments. Chemical data for protons are reported in parts per million (ppm) downfield from tetramethylsilane and are referenced to the residual proton in the NMR solvent (CDCl₃, 7.26 ppm; CD₃OD, 3.31 ppm; DMSO- d_6 2.51 ppm). The carbon nuclear magnetic resonance spectra (¹³C NMR) were recorded at 100 MHz: chemical data for carbons are reported in parts per million (ppm, δ scale) downfield from tetramethylsilane and are referenced to the carbon resonance of the solvent (CDCl₃, 77.16 ppm; CD₃OD, 49.0; DMSO- d_6 39.51 ppm). ESI-MS spectra were recorded on Agilent 1100 LC-Q-TOF. IR spectra were recorded on Perkin-Elmer IR spectrophotometer.

Procedure for synthesis of substituted 2-aryl-N benzyl benzimidazoles and 2-aryl benzimidazoles: To a solution of substituted *o*-phenylenediamine 1 (1 equiv.) in 3 mL of DMSO was added 10% w/w of Cu-Mn B, 2.5 equiv of K_2CO_3 and 2 equiv. of benzyl bromide 2 (2 equiv.) and heated at 100 °C for 12h. After completion of reaction monitored by TLC, reaction mixture was filtered to recover the catalyst. Water and ethyl acetate work up was done, organic layer was separated, dried over anhydrous sodium sulphate and finally concentrated to get crude product. The residue was subjected to purification by 100-200 silica gel column using EtOAc/hexane as eluent to get the desired products 3(a-q) in 48-72% and 4(a-q) in 12-22 % yield.

1-benzyl-2-phenyl-1H-benzo[d]imidazole (3a)¹



¹HNMR (400 MHz, CDCl₃) δ 7.92 (d, *J* = 8Hz, 1H), 7.73-7.71 (m, 2H), 7.51-7.47 (m, 3H), 7.38-7.32 (m, 4H), 7.28-7.23 (m, 2H), 7.14 (d, *J* = 8Hz, 2H), 5.48 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 154.2, 143.2, 136.4, 136.1, 129.3, 129.1, 128.8, 125.9, 123.1, 122.7, 119.9, 110.5, 48.4; ESI-MS (LTQ): 285.21 [M+H]⁺

1-(4-methylbenzyl)-2-(p-tolyl)-1H-benzo[d]imidazole (3b)²



¹HNMR (400 MHz, CDCl₃) δ 7.98 (d, *J* = 8Hz, 1H), 7.88 (d, *J* = 8Hz, 1H), 7.61 (d, *J* = 8Hz, 2H), 7.33-7.30 (m, 2H), 7.27-7.24 (m, 2H), 7.17 (d, *J* = 8Hz, 2H), 7.03 (d, *J* = 8Hz, 2H), 5.44 (s, 2H), 2.41 (s, 3H), 2.36 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 154.5, 140.2, 137.5, 133.3, 129.7, 129.5, 129.1, 126.7, 125.9, 125.7, 122.9, 122.7, 119.7, 110.6, 48.2, 21.4, 21.1; IR (CHCl₃): v_{max} 3410, 2919, 1621, 1429, 1274, 1083, 963 cm⁻¹; ESI-MS (LTQ): 313.14 [M+H]⁺

1-(3-methylbenzyl)-2-(m-tolyl)-1H-benzo[d]imidazole (3c)³



¹ HNMR (400 MHz, CDCl₃) δ 7.91 (d, J = 8Hz, 1H), 7.61 (s, 1H), 7.46 (d, J = 8Hz, 1H), 7.34-7.22 (m, 6H), 7.14 (d, J = 8Hz, 1H), 6.96-6.92 (m, 2H), 5.44 (s, 2H), 2.40 (s, 3H), 2.33 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 154.4, 143.1, 138.8, 138.7, 136.5, 130.7, 128.9, 128.5, 126.7, 123.1, 122.9, 110.6, 48.5, 21.5, 21.4; ESI-MS (LTQ): 313.17 [M+H]⁺

1-(4-fluorobenzyl)-2-(4-fluorophenyl)-1H-benzo[d]imidazole (3d)⁴



¹HNMR (400 MHz, CDCl₃) δ 7.88 (d, *J* = 8Hz, 1H), 7.66-7.63 (m, 2H), 7.34-7.30 (m, 1H), 7.27-7.19 (m, 2H), 7.16 (t, *J* = 8Hz, 2H), 7.04-7.00 (m, 4H), 5.37 (s, 2H); IR (CHCl₃): v_{max} 2956, 2924, 1711, 1607, 1509, 1482, 1458, 1414, 1381, 1226, 1157 cm⁻¹; ESI-MS (LTQ): 321.51 [M+H]⁺

1-(4-bromobenzyl)-2-(4-bromophenyl)-1H-benzo[d]imidazole (3e)⁵



¹HNMR (400 MHz, CDCl₃) δ 7.91 (d, *J* = 8Hz, 1H), 7.65 (t, *J* = 8Hz, 2H), 7.55 (d, *J* = 8Hz, 2H), 7.51 (d, *J* = 8Hz, 2H), 7.39-7.30 (m, 2H), 7.23 (d, *J* = 8Hz, 1H), 7.00 (d, *J* = 8Hz, 2H), 5.40 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 152.3, 142, 139.4, 135.1, 132.4, 132.1, 130.6, 129.3, 128, 123.6, 123.1, 122, 120.1, 111.6, 110.3, 47.9; IR (CHCl₃): v_{max} 2925, 1733, 1455, 1260, 1012 cm⁻¹; ESI-MS (LTQ): 341. 40[M+2H]⁺

1-(3-bromobenzyl)-2-(3-bromophenyl)-1H-benzo[d]imidazole (3f)⁴



¹ HNMR (400 MHz, CDCl₃) δ 7.91-786 (m, 1H), 7.62 (d, J = 8Hz, 1H), 7.54 (d, J = 8Hz, 1H), 7.48 (d, J = 8Hz, 1H), 7.39-7.26 (m, 6H), 7.24 (t, J = 8Hz, 1H), 5.42 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 154.4, 142.8, 138.3, 133.2, 132.3, 131.3, 130.8, 130.3, 129.2, 127.5, 126, 125, 124.6, 123.8, 123.3, 123.2, 123, 120.2, 110.4, 47.9; IR (CHCl₃): v_{max} 2957, 2923, 2870, 1713, 1597, 1571, 1456, 1379, 1248, 1190, 1160, 1072 cm⁻¹; ESI-MS (LTQ): 341.97 [M+H]⁺

1-(4-isopropylbenzyl)-2-(4-isopropylphenyl)-1H-benzo[d]imidazole (3g)⁶



¹ HNMR (400 MHz, CDCl₃) δ 7.89 (d, J = 8Hz, 1H), 7.68 (d, J = 12 Hz, 2H), 7.35-7.30 (m, 4H), 7.25-7.20 (m, 5H), 7.08 (d, J = 8Hz, 2H), 5.47 (s, 2H), 1.30 (s, 3H), 1.29 (s, 3H), 1.27 (s, 3H), 1.25 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 154.4, 150.9, 148.4, 143.2, 136.1, 133.8, 129.3, 127.5, 127.1, 126.9, 125.9, 122.8, 122.5, 119.8, 110.6, 48.2, 34.1, 33.8, 23.9, 23.8; IR (CHCl₃): v_{max} 2959, 2904, 1613, 1513, 1458, 1417, 1383, 1361, 1329, 1276, 1254, 1161, 1054, 1018 cm^{-1;} ESI-MS (LTQ): 369.21 [M+H]⁺

1-benzyl-5-nitro-2-phenyl-1H-benzo[d]imidazole (3h)⁷



¹ HNMR (400 MHz, CDCl₃) δ 8.79 (s, 1H), 8.22 (dd, J = 8, 12 Hz, 1H), 7.33 (d, J = 8Hz, 2H), 7.62-7.51 (m, 3H), 7.41-7.36 (m, 2H), 7.30 (d, J = 8Hz, 2H), 7.11 (d, J = 8Hz, 2H), 5.54 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 153.1, 144.1, 142.5, 140.2, 135.2, 130.8, 129.4, 129.3, 129.1, 128.3, 125.9, 118.8, 116.6, 110.5, 48.8; ESI-MS (LTQ): 330.08 [M+H]⁺

1-(3-methylbenzyl)-5-nitro-2-(m-tolyl)-1H-benzo[d]imidazole (3i)



Yellow semi solid; ¹ HNMR (400 MHz, CDCl₃) δ 8.77 (s, 1H), 8.20 (dd, J = 8, 12 Hz, 1H), 7.60 (s, 1H), 7.47 (d, J = 8Hz, 1H), 7.39 (d, J = 8Hz, 2H), 7.30-7.24 (m, 2H), 7.17 (d, J = 8Hz, 1H), 6.91 (t, J = 8Hz, 2H), 5.49 (s, 2H), 2.42 (s, 3H), 2.33 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 157.9, 144, 142.5, 139.1, 139, 135.3, 131.6, 130.2, 129.2, 129, 128.8, 126.6, 126, 122.9, 118.8, 116.5, 110.5, 48.9, 21.5, 21.4; IR (CHCl₃): v_{max} 3430, 2923, 1634, 1522, 1454, 1341 cm⁻¹; ESI-MS (LTQ): 358.16 [M+H]⁺; HRMS (ESI): m/z 358.1540 calcd for C₂₂H₁₉N₃O₂+H⁺ (358.1550).

1-benzyl-5-chloro-2-phenyl-1H-benzo[d]imidazole (3j)¹



¹HNMR (400 MHz, CDCl₃) δ 7.86 (d, *J* = 1.8Hz, 1H), 7.71 (t, *J* = 8Hz, 2H), 7.53-7.47 (m, 3H), 7.39-7.33 (m, 3H), 7.23-7.20 (m, 1H), 7.13-7.08 (m, 3H), 5.46 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 155.4, 144, 136, 135, 130.2, 129.3, 129.2, 129.2, 128.9, 128.8, 128, 126, 123.5, 120, 111.3, 48.6; IR (CHCl₃): v_{max} 2956, 2924, 1714, 1604, 1454, 1379, 1078 cm⁻¹; ESI-MS (LTQ): 319.01 [M+H]⁺

1-(4-bromobenzyl)-2-(4-bromophenyl)-5-chloro-1H-benzo[d]imidazole (3k)



Yellow Semisolid; ¹HNMR (400 MHz, CDCl₃+MeOD) δ 7.79 (d, *J*=8Hz, 1H), 7.63 (d, *J*=8Hz, 2H), 7.53 (d, *J*=8Hz, 3H), 7.33 (d, *J*=8Hz, 1H), 7.27 (d, *J*=8Hz, 1H), 7.21 (s, 1H), 6.97 (d, *J*=8Hz, 2H), 5.36 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 141.6, 139.8, 134.5, 132.5, 132.2, 131.6, 130.5, 129.3, 128.6, 127.4, 125, 123.9, 122.2, 121, 110.4, 47.9; IR (CHCl₃): v_{max} 2957, 2924, 1709, 1596, 1465, 1400, 1378, 1072, 1011 cm⁻¹; ESI-MS (LTQ): 475.52 [M+2H]⁺; HRMS (ESI): m/z 474.9214 calcd for C₂₀H₁₃Br₂ CIN₂+H⁺ (474.9207).

1-benzyl-5-methyl-2-phenyl-1H-benzo[d]imidazole (3l)⁸



¹ HNMR (400 MHz, CDCl₃) δ 7.78 (d, J = 8Hz, 1H), 7.71-7.68 (m, 2H), 7.48-7.45 (m, 3H), 7.39-7.33 (m, 3H), 7.17-7.03 (m, 4H), 5.45 (s, 2H), 2.46 (s, 3H)IR (CHCl₃): v_{max} 3031, 2956, 2924, 2854, 1715, 1606, 1454, 1386, 1357, 1329, 1260, 1170, 1076, 1029 cm⁻¹ESI-MS (LTQ): 299.12 [M+H]⁺

5-methyl-1-(4-methylbenzyl)-2-(p-tolyl)-1H-benzo[d]imidazole (3m)⁹



¹HNMR (400 MHz, CDCl₃) δ 7.76 (d, J = 8Hz, 1H), 7.60-7.57 (m, 2H), 7.28-7.25 (m, 3H), 7.18 (t, J = 8Hz, 2H), 7.09-7.00 (m, 3H), 5.39 (s, 2H), 2.45 (s, 3H), 2.42 (s, 3H), 2.37 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 153.9, 139.9, 137.4, 133.6, 132.8, 129.7, 129.6, 129.4, 129.1, 129.0, 125.9, 125.8, 124.3, 124.2, 119.3, 110.3, 110, 48.1, 21.9, 21.4, 21.1; IR (CHCl₃): v_{max} 2956, 2923, 1712, 1459, 1378, 1275 cm⁻¹; ESI-MS (LTQ): 327.69 [M+H]⁺

1-(4-bromobenzyl)-2-(4-bromophenyl)-5-methyl-1H-benzo[d]imidazole (3n)



White semisolid; ¹HNMR (400 MHz, CDCl₃) δ 7.78 (d, *J* = 8Hz, 1H), 7.54-7.43 (m, 5H), 7.19-7.10 (m, 2H), 7.00-7.96 (m, 3H), 5.36 (s, 2H), 2.47 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 152.4, 143.3, 135.3, 133.7, 132.9, 132.3, 132.1, 130.6, 128.9, 127.5, 124.8, 121.8, 110.1, 47.7, 21.9; IR (CHCl₃): v_{max} 2956, 2924, 2854, 1713, 1594, 1488, 1461, 1404, 1378, 1251, 1073, 1011 cm⁻¹; ESI-MS (LTQ): 455.55 [M+2H]⁺; HRMS (ESI): m/z 454.9763 calcd for C₂₁H₁₆Br₂N₂+H⁺ (454.9753).

1-benzyl-5-chloro-6-nitro-2-phenyl-1H-benzo[d]imidazole (30)



White semisolid; ¹HNMR (400 MHz, CDCl₃) δ 8.41 (s, 1H), 7.97 (s, 1H), 7.74 (t, *J* = 8Hz, 2H), 7.55-7.52 (m, 3H), 7.41-7.33 (m, 3H), 7.09 (d, *J* = 4HZ, 2H), 5.53 (d, *J* = 16Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 159.4, 145.9, 141, 138.6, 134.8, 133.8, 131.1, 129.5, 129.3, 129.1, 125.8, 122.4, 117.9, 112.9, 48.9; IR (CHCl₃): v_{max} 2957, 2924, 1732, 1616, 1585, 1528, 1445, 1379,

1327, 1260, 1150, 1079, 1028, 1006 cm⁻¹; ESI-MS (LTQ): 364. 43 [M+H]⁺; HRMS (ESI): m/z 364.0847 calcd for C₂₀H₁₄N₃O₂Cl+H⁺ (364.0847).

1-benzyl-5,6-dichloro-2-phenyl-1H-benzo[d]imidazole (3p)¹⁰



¹ HNMR (400 MHz, CDCl₃) δ 7.95 (s, 1H), 7.70 (d, J = 8Hz, 2H), 7.55-7.47 (m, 3H), 7.41-7.35 (m, 3H), 7.31 (s, 1H), 7.10 (d, J = 8Hz, 2H), 5.44 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 156.1, 142.5, 135.4, 130.5, 129.3, 129.2, 129.1, 128.9, 128.2, 126.9, 125.8, 121.1, 111.8, 48.6; ESI-MS (LTQ): 353.01 [M+H]⁺

Monosubstituted Benzimidazole

2-phenyl-1H-benzo[d]imidazole (4a)¹¹



¹ HNMR (400 MHz, CDCl₃) δ 12.93 (s, 1H (NH)), 8.21 (d, J = 8 Hz, 2H), 7.69 (d, J = 8 Hz, 1H), 7.58-7.48 (m, 4H), 7.23 (t, J = 8 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 151.7, 144.3, 135.5, 130.6, 130.3, 129.4, 126.9, 122.9, 122.1, 119.3, 111.8; IR (CHCl₃): v_{max} 2955.1, 2920.8, 2870.4, 1713.2, 1458.4, 1377.9, 1275, 1260.7, 1187.8, 1081.5, 1019 cm⁻¹; ESI-MS (LTQ): 195.20 [M+H] ⁺

2-(p-tolyl)-1H-benzo[d]imidazole (4b)¹²



¹ HNMR (400 MHz, CDCl₃) δ 7.98 (d, J = 8Hz, 2H), 7.66 (s, 2H), 7.34 (d, J = 8Hz, 2H), 7.30-7.28 (m, 2H), 2.44 (s, 3H); IR (CHCl₃): v_{max} 3410, 2919, 1621, 1429, 1274, 1083 cm⁻¹; ESI-MS (LTQ): 209.05 [M+H]⁺

2-(m-tolyl)-1H-benzo[d]imidazole (4c)¹³



¹ HNMR (400 MHz, CDCl₃+MeOD) δ 7.98-7.89 (m, 2H), 7.65 (m, 2H), 7.33-7.28 (m, 4H), 2.30 (s, 3H); ¹³C NMR (100 MHz, CDCl₃+MeOD) δ 156.1, 142.6, 134.7, 133.6, 132.7, 131.2, 127.6, 126.50, 25.1; IR (CHCl₃): v_{max} 3418, 2957, 2923, 1633, 1455, 1378, 1309 cm⁻¹; ESI-MS (LTQ): 209.04 [M+H]⁺

2-(4-fluorophenyl)-1H-benzo[d]imidazole (4d)¹⁴



¹ HNMR (400 MHz, CDCl₃) δ 8.10-8.07 (m, 2H), 7.67-7.65 (m, 2H), 7.31-7.27 (m, 2H), 7.20 (t, J = 8Hz, 2H); IR (CHCl₃): v_{max} 2918, 1600, 1496, 1429, 1395, 1275, 1227, 1083 cm⁻¹; ESI-MS (LTQ): 212.98 [M+H]⁺

2-(4-bromophenyl)-1H-benzo[d]imidazole (4e)¹⁵



¹ HNMR (400 MHz, CDCl₃) δ 7.96 (d, J = 8Hz, 2H), 7.68 (d, J = 8Hz, 4H), 7.34-7.31 (m, 2H); IR (CHCl₃): v_{max} 2923, 1427, 1275, 749 cm⁻¹; ESI-MS (LTQ): 272.95 [M+H]⁺

2-(3-bromophenyl)-1H-benzo[d]imidazole (4f)



Yellow oil; ¹ HNMR (400 MHz, CDCl₃+MeOD) δ 8.18 (s, 1H), 7.98 (d, *J* = 8Hz, 1H), 7.51 (d, *J* = 8Hz, 1H), 7.31-7.27 (m, 2H), 7.21-7.19 (m, 2H); ¹³C NMR (100 MHz, CDCl₃+MeOD) δ 150.3, 132.7, 131.9, 130.4, 129.5, 125.2, 122.9; IR (CHCl₃): ν_{max} 2955, 2917, 1709, 1589, 1436, 1399, 1119 cm⁻¹; ESI-MS (LTQ): 273.05 [M+2H]⁺

2-(4-isopropylphenyl)-1H-benzo[d]imidazole (4g)¹⁶



¹ HNMR (400 MHz, CDCl₃) δ 8.03 (d, J = 8Hz, 2H), 7.66-7.64 (m, 2H), 7.36 (d, J = 2H), 7.29-7.27 (m, 3H), 1.31 (s, 3H), 1.29 (s, 3H); IR (CHCl₃): v_{max} 2956, 2920, 1590, 1434, 1400, 1275, 1111, 969 cm⁻¹; ESI-MS (LTQ): 237.06 [M+H]⁺

5-nitro-2-(m-tolyl)-1H-benzo[d]imidazole (4i)¹⁷



¹ HNMR (400 MHz, CDCl₃) δ 8.74 (s, 1H), 8.31 (d, *J* = 8Hz, 1H), 7.65 (s, 1H), 7.57 (d, *J* = 8Hz, 1H), 7.49-7.46 (m, 2H), 7.42 (d, *J* = 8Hz, 1H), 2.49 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 157.6, 143.9, 142.2, 140.6, 139, 131.4, 130.2, 128.9, 128.8, 126.3, 118.6, 116.5, 109.5, 21.5; IR (CHCl₃): v_{max} 2924, 1520, 1464, 1320, 1276, 1053 cm⁻¹; ESI-MS (LTQ): 254.04 [M+H]⁺

5-methyl-2-phenyl-1H-benzo[d]imidazole (4l)¹⁸



¹ HNMR (400 MHz, CDCl₃) δ 8.09 (s, 2H), 7.55 (d, J = 12 Hz, 1H), 7.44-7.42 (m, 3H), 7.39 (s, 1H), 7.10 (d, J = 8Hz, 1H), 2.47 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 151.5, 132.9, 130, 129.8, 129, 126.6, 124.5, 21.7; IR (CHCl₃): v_{max} 2924, 1629, 1455, 1276, 1026 cm⁻¹; ESI-MS (LTQ): 209.02 [M+H]⁺

5-methyl-2-(p-tolyl)-1H-benzo[d]imidazole (4m)¹⁹



¹ HNMR (400 MHz, CDCl₃) δ 8.02 (d, J = 8Hz, 2H), 7.51 (d, J = 8Hz, 1H), 7.36 (s, 1H), 7.20 (d, J = 8Hz, 2H), 7.07 (d, J = 8Hz, 1H), 2.44 (s, 3H), 2.36 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 151.9, 140.2, 138.7, 137.7, 132.7, 129.7, 127.1, 126.6, 124.3, 115, 114.4, 21.7, 21.4; IR (CHCl₃): v_{max} 3418, 2957, 2923, 1633, 1455, 1378, 1309 cm⁻¹; ESI-MS (LTQ): 223.32 [M+H]⁺

2-(4-bromophenyl)-5-methyl-1H-benzo[d]imidazole (4n)²⁰



¹ HNMR (400 MHz, CDCl₃) δ 7.92 (d, J = 8Hz, 2H), 7.60 (d, J = 8Hz, 2H), 7.55 (d, J = 8Hz, 1H), 7.40 (s, 1H), 7.13 (d, J = 8Hz, 1H), 2.49 (s, 3H); IR (CHCl₃): v_{max} 3424, 2953, 2916, 1633, 1427, 1377, 1271, 1071, 1009 cm⁻¹; ESI-MS (LTQ): 288.17 [M+2H]⁺

5,6-dichloro-2-phenyl-1H-benzo[d]imidazole (4p)²¹



¹ HNMR (400 MHz, CDCl₃) δ 7.90 (s, 1H), 7.77-7.75 (m, 2H), 7.57-7.55 (m, 3H), 7.52 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 155.9, 142.1, 130.3, 129.6, 129.4, 128.9, 128.8, 120.9, 111.1; IR (CHCl₃): v_{max} 2924, 1629, 1455, 1276, 1026 cm⁻¹; ESI-MS (LTQ): 263.10 [M+H]⁺

S2. Scanned copies of ¹H , ¹³C NMR and HRMS spectra of compounds.

¹H and ¹³C NMR spectra's of 1-benzyl-2-phenyl-1H-benzo[d]imidazole (3a).





¹H and ¹³C NMR spectra of 1-(4-methylbenzyl)-2-(p-tolyl)-1H-benzo[d]imidazole (3b).





¹H and ¹³C NMR spectra of 1-(3-methylbenzyl)-2-(m-tolyl)-1H-benzo[d]imidazole (3c).





¹H and ¹³C NMR spectra's of 1-(4-fluorobenzyl)-2-(4-fluorophenyl)-1H-benzo[d]imidazole (3d).



¹H and ¹³C NMR spectra of 1-(4-bromobenzyl)-2-(4-bromophenyl)-1H-benzo[d]imidazole (3e).





¹H and ¹³C NMR spectra of 1-(3-bromobenzyl)-2-(3-bromophenyl)-1H-benzo[d]imidazole (3f).











¹H and ¹³C NMR spectra of 1-benzyl-5-nitro-2-phenyl-1H-benzo[d]imidazole (3h).

¹H, ¹³C NMR and HRMS spectra of 1-(3-methylbenzyl)-5-nitro-2-(m-tolyl)-1Hbenzo[d]imidazole (3i).



Elemental Composition Report

Single Mass Analysis Tolerance = 5.0 PPM / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 3 Monoisotopic Mass, Even Electron Ions 76 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass) Elements Used: C: 0-25 H: 0-20 N: 0-4 O: 0-4 CI: 0-1
 Sample Name
 : PR-75-A

 Test Name
 : HRMS-1

 280119-PR-75-A
 18 (0.183) AM2 (Ar, 19000.0,0.00,0.00); Cm (18:26)
I.I.T.ROPAR XEVO G2-XS OTOF 1: TOF MS ES+ 1.24e+008 358.1540 100-% 359.1576 346.0175 360.1607 194.1179 224.1269 274.2726 462.2201 517.1241 551.5106 0-· · · · · 600 150 250 450 500 200 300 350 400 Minimum: -1.5 Maximum: 5.0 5.0 50.0 DBE i-FIT Norm Conf(%) Formula Mass Calc. Mass mDa PPM 358.1540 358.1556 -1.6 -4.5 14.5 766.8 n/a n/a C22 H20 N3 O2

¹H and ¹³C NMR spectra of 1-benzyl-5-chloro-2-phenyl-1H-benzo[d]imidazole (3j).

Page 1





¹H, ¹³C NMR and HRMS spectra of 1-(4-bromobenzyl)-2-(4-bromophenyl)-5-chloro-1Hbenzo[d]imidazole (3k).



Elemental Composition Report

Single Mass Analysis Tolerance = 5.0 PPM / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions 28 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass) Elements Used: C: 0-25 H: 0-20 N: 0-3 CI: 0-1 Br: 0-2



Page 1











¹H, ¹³C NMR and HRMS spectra of 1-(4-bromobenzyl)-2-(4-bromophenyl)-5-methyl-1Hbenzo[d]imidazole (3n).





Elemental Composition Report

Page 1

Single Mass Analysis Tolerance = 5.0 PPM / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions 16 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass) Elements Used: C: 0-25 H: 0-20 N: 0-4 Br: 0-2

Sample Name : PR-80-A I.I.T.RO Test Name : HRMS-1 280119-PR-80-A 18 (0.183) AM2 (Ar,19000.0,0.00,0.00); Cm (18:26) I.I.T.ROPAR XEVO G2-XS QTOF 1: TOF MS ES+ 9.62e+007 456.9742 100-454.9763 458.9726 % 459.9759 460.9804 170.9635 274.2729 358.1570 454.8838 0-1---200 250 400 500 300 350 550 450 Minimum: -1.5 50.0 5.0 5.0 Maximum: Calc. Mass mDa PPM DBE i-FIT Norm Conf(%) Formula Mass 454.9763 454.9758 0.5 1.1 13.5 637.9 n/a n/a C21 H17 N2 Br2

¹H ,¹³C NMR and HRMS spectra of 1-benzyl-5-chloro-6-nitro-2-phenyl-1H-benzo[d]imidazole (30).





¹H and ¹³C NMR spectra of 1-benzyl-5,6-dichloro-2-phenyl-1H-benzo[d]imidazole (3p).





¹H and ¹³C NMR spectra of 2-phenyl-1H-benzo[d]imidazole (4a).

¹H NMR spectra of 2-(p-tolyl)-1H-benzo[d]imidazole (4b).





¹H and ¹³C NMR spectra of 2-(m-tolyl)-1H-benzo[d]imidazole (4c).



¹H NMR spectra of 2-(4-fluorophenyl)-1H-benzo[d]imidazole (4d).

¹H NMR spectra of 2-(4-bromophenyl)-1H-benzo[d]imidazole (4e).









¹H NMR spectra of 2-(4-isopropylphenyl)-1H-benzo[d]imidazole (4g).

¹H and ¹³C NMR spectra of 5-nitro-2-(m-tolyl)-1H-benzo[d]imidazole (4i)







¹H and ¹³C NMR spectra of 5-methyl-2-phenyl-1H-benzo[d]imidazole (4l)

180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 f1 (num)



¹H and ¹³C NMR spectra of 5-methyl-2-(p-tolyl)-1H-benzo[d]imidazole (4m).



¹H NMR spectra of 2-(4-bromophenyl)-5-methyl-1H-benzo[d]imidazole (4n).





¹H and ¹³C NMR spectra of 5,6-dichloro-2-phenyl-1H-benzo[d]imidazole (4p).

S3. REFERENCES

- 1. C. Xie, X. Han, J. Gong, D. Li and C. Ma, Org. Biomol. Chem., 2017, 15, 5811-5819.
- 2. L.-J. Zhang, J. Xia, Y.-Q. Zhou, H. Wang and S.-W. Wang, *Synth. Commun.*, 2012, 42, 328-336.
- 3. P. Wang, J. Wang, C.-T. Au, R. Qiu, X. Xu and S.-F. Yin, *Adv. Synth. Catal.*, 2016, 358, 1302-1308.
- 4. Y. R. Girish, K. S. Sharath Kumar, K. N. Thimmaiah, K. S. Rangappa and S. Shashikanth, *RSC Adv.*, 2015, 5, 75533-75546.
- 5. R. Jamatia, M. Saha and A. K. Pal, *RSC Adv.*, 2014, 4, 12826-12833.
- 6. S. Senthilkumar and M. Kumarraja, *Tetrahedron Lett.*, 2014, 55, 1971-1974.
- 7. F. A. Romero and R. Moningka, *Tetrahedron Lett.*, 2010, 51, 4459-4461.
- 8. D. N. Kommi, D. Kumar, R. Bansal, R. Chebolu and A. K. Chakraborti, *Green Chem.*, 2012, 14, 3329-3335.
- 9. Z. Xu, X. Yu, X. Sang and D. Wang, Green Chem., 2018, 20, 2571-2577.
- 10. R. Varala, A. Nasreen, R. Enugala and S. R. Adapa, *Tetrahedron Lett.*, 2007, 48, 69-72.
- 11. R. Sharma, M. Abdullaha and S. B. Bharate, Asian J. Org. Chem., 2017, 6, 1370-1374.
- 12. A. Farrokhi, M. Jafarpour and F. Feizpour, *ChemistrySelect*, 2018, 3, 1234-1241.
- 13. R. Zhang, Y. Qin, L. Zhang and S. Luo, Org. Lett., 2017, 19, 5629-5632.
- 14. M. Saha, P. Mukherjee and A. R. Das, *Tetrahedron Lett.*, 2017, 58, 1046-1049.
- 15. J. Feng, S. Handa, F. Gallou and B. H. Lipshutz, *Angew. Chem. Int. Ed.*, 2016, 55, 8979-8983.
- 16. H. Sharghi, M. Aberi and M. M. Doroodmand, Adv. Synth. Catal., 2008, 350, 2380-2390.
- 17. L. Shi, T.-T. Wu, Z. Wang, J.-Y. Xue and Y.-G. Xu, *Bioorg. Med. Chem.*, 2014, 22, 4735-4744.
- 18. H. Hikawa, R. Ichinose, S. Kikkawa and I. Azumaya, *Asian J. Org. Chem.*, 2018, 7, 416-423.
- 19. P. Daw, Y. Ben-David and D. Milstein, ACS Catalysis, 2017, 7, 7456-7460.
- 20. S. Lin and L. Yang, *Tetrahedron Lett.*, 2005, 46, 4315-4319.
- 21. U. Narang, K. K. Yadav, S. Bhattacharya and S. M. S. Chauhan, *ChemistrySelect*, 2017, 2, 7135-7140.